Gratus Wealth Advisors LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Gratus Wealth Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 33.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,721 shares of the company’s stock after buying an additional 434 shares during the period. Gratus Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,546,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Capital Planning LLC bought a new position in shares of Eli Lilly and Company during the first quarter worth $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Eli Lilly and Company during the first quarter valued at about $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $8,896,000. HighPoint Advisor Group LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth $9,878,000. Finally, Leo Wealth LLC purchased a new stake in Eli Lilly and Company during the fourth quarter valued at $3,355,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.7 %

Shares of NYSE LLY opened at $913.72 on Wednesday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The firm has a market cap of $868.40 billion, a PE ratio of 134.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. The business has a fifty day simple moving average of $901.94 and a two-hundred day simple moving average of $849.30. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.